Xyntha approved for hemophilia A

Xyntha approved for hemophilia A
Xyntha approved for hemophilia A
The FDA has approved Wyeth's Xyntha (recombinant antihemophilic factor VIII) for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A.

The FDA has approved Wyeth’s Xyntha (recombinant antihemophilic factor VIII) for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A. Xyntha is plasma/albumin-free and is not derived from animal or human sources. Xyntha is expected to be available in September 2008.

For more information call (800) 934-5556 or visit www.xyntha.com.